Onxeo to Present Five Preclinical Studies Highlighting AsiDNA Unique Profile and its clinical potential in Oncology at 2019 American Association for Cancer Research Annual Meeting

Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), ("Onxeo" or "the Company"), a clinical-stage biotechnology company specializing in the development of innovative drugs targe...

More From BioPortfolio on "Onxeo to Present Five Preclinical Studies Highlighting AsiDNA Unique Profile and its clinical potential in Oncology at 2019 American Association for Cancer Research Annual Meeting"